Loading...
XKRX000105
Market cap5.63bUSD
Dec 20, Last price  
99,800.00KRW
1D
-2.16%
1Q
-36.68%
Jan 2017
329.03%
Name

Yuhan Corp

Chart & Performance

D1W1MN
XKRX:000105 chart
P/E
54.12
P/S
3.96
EPS
1,844.18
Div Yield, %
0.37%
Shrs. gr., 5y
1.64%
Rev. gr., 5y
4.12%
Revenues
1.86t
+4.68%
493,285,310,000611,185,646,000646,772,504,000663,570,311,000679,230,981,630776,457,613,410943,609,130,8001,017,491,786,4201,128,731,291,6501,320,797,335,2901,462,248,030,1401,518,822,858,4301,480,353,606,9401,619,865,302,6801,687,810,317,7401,775,846,942,7401,858,983,759,650
Net income
93.51b
-1.72%
92,073,194,000125,644,189,000121,737,854,000128,001,500,00094,217,471,13080,775,749,00086,461,208,09090,947,777,980126,046,994,760161,248,743,740109,034,185,95057,480,741,11040,006,186,810192,761,176,870102,582,679,18095,144,301,42093,509,563,680
CFO
144.13b
+44.81%
97,847,667,000123,117,050,000134,380,244,000149,592,249,00072,377,880,73072,379,345,17079,777,958,88094,385,653,450126,234,690,91074,144,086,540126,125,107,52093,451,633,13065,985,413,05028,830,248,88099,000,468,38099,528,971,400144,128,102,312
Dividend
Dec 27, 2023460 KRW/sh
Earnings
Feb 04, 2025

Profile

Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.
URL
https://www.yuhan.co.kr/
IPO date
Nov 01, 1962
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,858,983,760
4.68%
1,775,846,943
5.22%
1,687,810,318
4.19%
Cost of revenue
1,604,933,638
1,565,143,942
1,460,348,910
Unusual Expense (Income)
NOPBT
254,050,122
210,703,001
227,461,407
NOPBT Margin
13.67%
11.86%
13.48%
Operating Taxes
4,708,853
4,333,847
26,934,059
Tax Rate
1.85%
2.06%
11.84%
NOPAT
249,341,269
206,369,154
200,527,348
Net income
93,509,564
-1.72%
95,144,301
-7.25%
102,582,679
-46.78%
Dividends
(27,268,933)
(26,079,622)
(24,940,677)
Dividend yield
0.50%
0.64%
0.53%
Proceeds from repurchase of equity
(7,457,004)
(16,521,185)
9,174,592
BB yield
0.14%
0.40%
-0.20%
Debt
Debt current
299,864
91,966,049
92,143,473
Long-term debt
634,634
7,661,539
39,711,911
Deferred revenue
400,000
354,000
Other long-term liabilities
128,978,124
(62,467,892)
36,798,002
Net debt
(939,539,381)
(815,343,670)
(865,037,887)
Cash flow
Cash from operating activities
144,128,102
99,528,971
99,000,468
CAPEX
(161,479,680)
(94,378,310)
(81,874,834)
Cash from investing activities
(187,075,209)
15,621,385
(167,143,274)
Cash from financing activities
51,092,658
(65,541,959)
(36,533,135)
FCF
299,506,301
131,024,232
187,572,222
Balance
Cash
322,003,511
347,718,179
436,803,488
Long term investments
618,470,368
567,253,079
560,089,783
Excess cash
847,524,691
826,178,911
912,502,755
Stockholders' equity
2,154,226,373
3,782,398,430
3,601,416,981
Invested Capital
1,606,976,466
1,188,312,448
1,142,491,039
ROIC
17.84%
17.71%
18.63%
ROCE
12.43%
10.01%
10.93%
EV
Common stock shares outstanding
78,714
75,185
75,593
Price
68,800.00
26.29%
54,476.19
-12.28%
62,100.00
-17.31%
Market cap
5,415,507,582
32.22%
4,095,773,878
-12.75%
4,694,353,742
-17.47%
EV
4,475,968,201
3,303,586,931
3,839,514,475
EBITDA
298,733,188
253,721,514
280,131,945
EV/EBITDA
14.98
13.02
13.71
Interest
2,455,080
3,468,047
2,943,971
Interest/NOPBT
0.97%
1.65%
1.29%